All In Biotech

Drug Trial Radar · NCT07409103

A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Feb 18, 2026

Primary completion

Apr 15, 2027

Study completion Mar 31, 2028

Sponsor

Lead sponsor
Elevara Medicines LimitedIndustry
Sponsor type
Industry
First posted
Feb 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 randomized, double-blind, placebo-controlled study with a total duration of 32 weeks from Screening to End-of-Study (EOS) Visit. Approximately 180 participants are planned to be enrolled. The number of participants can be extended to maximally 220 to account for dropouts during the study.

Conditions

  • Active Rheumatoid Arthritis

Interventions

  • ELV001 25 mgDrug

    25mg from week 0 to week 12 then ELV001 75mg or 125mg per day from week 12 to week 24

  • ELV001 75 mgDrug

    75mg from week 0 to week 24

  • ELV001 125 mgDrug

    125mg from week 0 to week 24

  • PlaceboDrug

    Placebo from week 0 to week 12, then ELV001 75mg or 125mg per day from week 12 to week 24.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Disease activity score 28- C-reactive protein between Baseline and Week 12.Time frame: From Baseline to week 12

Locations

34 sites in 3 countries. Site status is shown where the registry gives one.

  • Arizona Arthritis & Rheumatology Associates

    Gilbert, Arizona · Recruiting

  • Arizona Arthritis & Rheumatology Associates

    Glendale, Arizona · Recruiting

  • Arizona Arthritis & Rheumatology Associates

    Tucson, Arizona · Recruiting

  • Solace Clinical Research - Populace Health (Network)

    Tustin, California · Recruiting

  • Denver Arthritis Clinic

    Denver, Colorado · Recruiting

  • Rheumatology Associates of South Florida-Clinical Research Inc - Cliniverse Research (Network)

    Boca Raton, Florida · Recruiting

  • Prophase, LLC - Clinitiative Health Research (Network)

    Margate, Florida · Recruiting

  • Millennium Medical Research LLC - Clinitiative Health Research (Network)

    Miami, Florida · Recruiting

  • Floridian Clinical Research, LLC - Clinitiative Health Research (Network)

    Miami Beach, Florida · Recruiting

  • Bioresearch Partner - Cliniverse Research (Network)

    South Miami, Florida · Recruiting

  • Accurate Clinical Research Inc (SMO/ Network)

    Lake Charles, Louisiana · Recruiting

  • Great Lakes Center of Rheumatology

    Lansing, Michigan · Recruiting

  • DJL Clinical Research PLLC (Network) cIRB

    Charlotte, North Carolina · Recruiting

  • Carolina Arthritis Associates - Cliniverse Research (Network)

    Wilmington, North Carolina · Recruiting

  • Altoona Arthritis & Osteoporosis Center

    Duncansville, Pennsylvania · Recruiting

  • Pennsylvania Regional Center for Arthritis & Osteoporosis Research

    Wyomissing, Pennsylvania · Recruiting

  • Accurate Clinical Management, LLC. - Accurate Clinical Research Inc (SMO/ Network)

    Baytown, Texas · Recruiting

  • Accurate Clinical Research Inc (SMO/ Network)

    Houston, Texas · Recruiting

  • Heights Rheumatology and Aesthetics - ES Clinical Research Group Network

    Jackson, Texas · Recruiting

  • Epic Medical Research-Red Oak

    Red Oak, Texas · Recruiting

  • DM Clinical Research (Network)

    Tomball, Texas · Recruiting

  • DM Clinical Research (Network)

    Tomball, Texas · Recruiting

  • Institute of Rheumatology

    Belgrade, Serbia · Recruiting

  • Institute of Rheumatology

    Belgrade, Serbia · Recruiting

  • Military Medical Academy,Clinic for Rheumatology

    Belgrade, Serbia · Recruiting

  • Special Hospital for Rheumatic Diseases Novi Sad

    Novi Sad, Vojvodina, Serbia · Recruiting

  • Panorama Medical Center

    Panorama, Cape Town, South Africa · Recruiting

  • The Arthritis Clinical Trial Centre

    Pinelands, Capetown, South Africa · Recruiting

  • Winelands Medical Research Centre - Somerset West (Dr Francois Bouwer INC)

    Somerset West, Capetown, South Africa · Recruiting

  • CRISMO Research Centre - Bertha Gxowa Hospital

    Germiston, Gauteng, South Africa · Recruiting

  • Clinical Research Unit, University of Pretoria, Room 2-54, Pathology Building, Prinshof Medical Campus Dr. Savage Road, incorporating Steve Biko Hospital, Steve Biko Road

    Pretoria, Gauteng, South Africa · Recruiting

  • Netcare Jakaranda Hospital Suite 102

    Pretoria, Gauteng, South Africa · Recruiting

  • Netcare Umhlanga Medical Centre

    Durban, KwaZulu-Natal, South Africa · Recruiting

  • Winelands Medical Research Centre

    Stellenbosch, Western Cape, South Africa · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.